WPA
FATE icon

Wealth Preservation Advisors’s Fate Therapeutics FATE Stock Holding History

Wealth Preservation Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$371 Buy
+309
New +$376 ﹤0.01% 815

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wealth Preservation Advisors's FATE Position: Q1 2026 in Review

Wealth Preservation Advisors opened a new position in Fate Therapeutics (FATE) in Q1 2026: 309 shares worth $371. The stake represents ﹤0.01% of the portfolio and ranks #815 among its holdings.

157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • Wealth Preservation Advisors held 309 shares of Fate Therapeutics worth $371 as of Q1 2026.
  • Fate Therapeutics was a new Wealth Preservation Advisors position in Q1 2026.
  • Fate Therapeutics made up ﹤0.01% of Wealth Preservation Advisors's portfolio in Q1 2026, its #815 holding.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on Wealth Preservation Advisors's 13F filing for Q1 2026, filed 15 May 2026.